BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AVAX Technologies (AVXT) Announces Collaboration With The University of Pennsylvania Health System Applying Its AC Vaccine Technology To The Treatment Of Non-Small Cell Lung Cancer


10/19/2005 5:12:48 PM

PHILADELPHIA--(BUSINESS WIRE)--Feb. 22, 2005-- AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announced that it has established a research collaboration with Dr. Joseph Friedberg, Chief of the Division of Thoracic Surgery at Presbyterian Medical Center, part of the University of Pennsylvania Health System, to conduct a clinical trial of its AC Vaccine in patients with non-small cell lung cancer (NSCLC). Presbyterian Medical Center and Hospital of the University of Pennsylvania, both part of the University of Pennsylvania Health System, will be the exclusive partner and clinical sites for the trial. AVAX and the University plan to submit an Investigational New Drug application (IND) for the treatment of patients with Stage I or II NSCLC to the U.S. Food and Drug Administration by March 31, 2005. The AC Vaccine consists of autologous, lung cancer cells from each patient modified with the hapten, dinitrophenyl (DNP). The laboratory work leading to the development of the new lung cancer vaccine will be the subject of a presentation to be made at a special conference sponsored by the American Association for Cancer Research, entitled, "Molecular Pathogenesis of Lung Cancer: Opportunities for Translation to the Clinic." The conference will be held in San Diego from February 23-27.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES